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The purpose of this study was to evaluate a single-step, organic solvent-free supercritical 
fluid process for the preparation of olanzapine-methyl-β-cyclodextrin complexes with an 
express goal to enhance the dissolution properties of olanzapine. The complexes were 
prepared by supercritical carbon dioxide processing, co-evaporation, freeze drying and 
physical mixing. The prepared complexes were then analysed by differential scanning 
calorimetry, X-ray powder diffraction, scanning electron microscopy, solubility and 
dissolution studies. Computational molecular docking studies were performed to study the 
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formation of molecular inclusion complexation of olanzapine with methyl-β-cyclodextrin. All 
the binary mixtures of olanzapine with methyl-β-cyclodextrin, except physical mixture, 
exhibited a faster and greater extent of drug dissolution than the drug alone. Products 
obtained by the supercritical carbon dioxide processing method exhibited the highest 
apparent drug dissolution. The characterisation by different analytical techniques suggests 
complete complexation or amorphisation of olanzapine and methyl-β-cyclodextrin complexes 
prepared by supercritical carbon dioxide processing method. Therefore, organic solvent-free 
supercritical carbon dioxide processing method proved to be novel and efficient for the 
preparation of solid inclusion complexes of olanzapine with methyl-β-cyclodextrin. The 
preliminary data also suggests that the complexes of olanzapine with methyl-β-cyclodextrin 




SC-CO2: Supercritical carbon dioxide 
SEM: Scanning electron microscopy 
DSC: Differential scanning calorimetry 
XRPD: X-ray powder diffraction 
DP: Percent drug dissolved 
DE: Dissolution efficiency 
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1. Introduction   
Olanzapine is a second-generation atypical neuroleptic drug approved by the Food and Drug 
Administration as a first-line therapy for the treatment of schizophrenia and mania associated 
with bipolar disorder (Abdelbary and Tadros, 2013). It suffers from poor aqueous solubility 
(12-44 µg mL-1) and a low dissolution rate leading to an erratic bioavailability (Kulkarni et 
al., 2010; Dixit et al., 2011; Raman et al., 2013). Moreover, the drug undergoes extensive 
hepatic first-pass metabolism and is required in high doses (Sood et al., 2013).  
Several approaches have been reported to enhance the solubility and dissolution rate of 
olanzapine, e.g. solid-dispersions (Krishnamoorthy et al., 2011), nano-emulsions (Raman et 
al., 2013), solid-lipid nanoparticles (Sood et al., 2013), freeze dried tablets (Dixit et al., 
2011) and inclusion complexation with cyclodextrins (Kulkarni et al., 2010; de Freitas et al., 
2012).   
Cyclodextrins, also known as cyclomaltoses, cycloamyloses and Schardinger dextrins, are 
macrocyclic oligomers of α-D-glucose with a hydrophilic exterior and a relatively non polar 
central cavity (Appel et al., 2012; Kfoury et al., 2014; Kfoury et al., 2015; Rudrangi et al., 
2015). Cyclodextrins can form inclusion complexes by taking up the entire or a part of 
lipophilic drug molecule in its hydrophobic interior cavity (Loftsson and Duchêne, 2007; 
Salústio et al., 2009). Through formation of inclusion complexes, cyclodextrins are known to 
enhance the aqueous solubility and dissolution rate of poorly soluble drugs (Trapani et al., 
2000; Pose-Vilarnovo et al., 2001; Latrofa et al., 2001; Jain and Adeyeye, 2001; Riekes et 
al., 2010). 
The study published by de Freitas et al. (2012) reported that olanzapine and methyl-β-
cyclodextrin (Me-β-CD) complexes prepared in the 1:1 molar ratio using rotary evaporation 
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method exhibit a higher dissolution profile than the active alone or in a state of physical 
mixture. Despite their success, the complex preparation by the stated method required an 
organic solvent which is not desirable. Removal of environmentally harmful organic solvents 
from the drug product to the levels approved by the Food and Drug Administration is very 
challenging and therefore conventional techniques used for the preparation of inclusion 
complexes (co-evaporation, spray drying and kneading) involve several drying steps for 
considerable time, which may also affect the drug stability (Al-Marzouqi et al., 2006). 
Hence, it is highly recommended to eliminate the use of organic solvents in the preparation of 
drugs or drug-cyclodextrin complexes.   
The aim of the present study was to produce olanzapine-Me-β-CD complexes in the same 
stoichiometric ratios (1:1 molar) without using organic solvents or auxiliary agents. 
Therefore, application of supercritical fluid processing was studied as an alternative to 
conventional methods in the current work.  
A supercritical fluid is defined as a substance that exists above its critical pressure and 
temperature. Supercritical fluids feature densities like liquids and viscosities and diffusivities 
like gases and hence offer excellent mass transfer and solubilising properties (York, 1999; 
Kompella and Koushik, 2001; Sunkara and Kompella, 2002; Bandi et al., 2004). Carbon 
dioxide becomes supercritical above 31.25 °C and 73.8 bar. Supercritical carbon dioxide 
(SC-CO2) is environmentally benign and is considered to be green. SC-CO2 is a non-
combustible, non-toxic, recyclable and environment-friendly solvent (Palakodaty and York, 
1999; Lang and Wai, 2001; Lee et al., 2008; Deshpande et al., 2011; Girotra et al., 2013; 
Rudrangi et al., 2015) and has provided an appealing alternative to toxic organic solvents or 
conventional complexation media. SC-CO2 has been successfully employed in the 
preparation of inclusion complexes between various drugs and cyclodextrins in dynamic or 




The use of the SC-CO2 processing has already been investigated in the preparation of drug-
Me-β-CD inclusion complexes (Charoenchaitrakool et al., 2002; Banchero et al., 2013; 
Rudrangi et al., 2015). A significant improvement in the dissolution rate of drug was 
observed in all cases.  It was suggested by Banchero and co-workers (Banchero et al., 2013) 
that the liquefaction of Me-β-CD in SC-CO2 favours the complexation of drug and 
cyclodextrin without any addition of water or auxiliary agents as the drug molecules would 
better reach the cavity of the cyclodextrin in the molten or liquid state.    
The effect of supercritical carbon dioxide processing on the preparation of olanzapine-Me-β-
CD complexes has not yet been reported. Inclusion complexes were prepared by physical 
mixing, freeze drying, co-evaporation and SC-CO2 processing at various working 
(temperature and pressure) conditions. The prepared complexes were then characterized by 
solubility studies, differential scanning calorimetry, X-ray powder diffraction, scanning 
electron microscopy and dissolution studies. 
 
2. Materials and methods  
2.1. Materials 
Olanzapine (≥99%, molecular weight: 312.44, CAS number: 132539-06-1) was obtained 
from Dr. Reddy's Laboratories Ltd. (Hyderabad, Telangana, India). Me-β-CD (average 
molecular weight: 1310, CAS number: 128446-36-6, extent of labeling: 1.6–2.0 mol CH3 per 
unit anhydroglucose) was purchased from Sigma–Aldrich (Gillingham, Dorset, UK). Carbon 
dioxide (99.9%) was obtained from BOC Ltd. (Guildford, Surrey, UK). All chemicals were 




2.2. Preparation of binary mixtures of olanzapine with Me-β-CD 
All binary mixtures of olanzapine with Me-β-CD were prepared in a 1:1 molar ratio. The 
processed samples were stored in a desiccator over solid calcium chloride until submitted for 
analysis. 
2.2.1. Physical mixing 
Physical mixture was obtained by tumble-mixing an accurately weighed equimolar mixture 
of olanzapine and Me-β-CD at 100 rpm for 15 minutes using a TURBULA® T2F mixer 
(Willy A. Bachofen AG – Maschinenfabrik, Muttenz, Switzerland). 
2.2.2. Freeze drying 
Olanzapine was added to the aqueous solution of Me-β-CD under constant stirring. The 
mixture was agitated in an orbital shaker at room temperature until equilibrium was attained 
(48 h). The resultant suspension was frozen at −60 °C and then lyophilized in a freeze-dryer 
(ScanVac CoolSafe, UK) for 48 h. The obtained product was sieved through 0.150 mm sieve. 
2.2.3. Co-evaporation 
An ethanolic solution of olanzapine was added to an aqueous solution of Me-β-CD and the 
mixture was agitated in an orbital shaker for 24 h. The solvents were then evaporated under 
reduced pressure to yield a pale yellowish, dry powder.  
2.2.4. Supercritical carbon dioxide process 
The complexes were prepared using an extraction apparatus supplied by Thar Process Inc., 
USA in the static mode. The schematics of SC-CO2 processing have been previously 
described in detail (Rudrangi et al., 2015). 
The physical mixtures of olanzapine and Me-β-CD (100.01 mg and 412.28 mg; 100.03 mg 
and 412.27 mg; 100.02 mg and 412.28 mg; 100.01 mg and 412.30 mg, respectively) were 
placed in a sample cell. Carbon dioxide was pumped from a cylinder via a cooling unit into 
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the sample cell. The physical mixtures were processed at four different working conditions 
[45 °C-100 bar, 45 °C-200 bar, 55 °C-100 bar and 55 °C-200 bar] in order to study the 
influence of pressure and temperature on the formation of inclusion complexes. 
The desired pressure was achieved by pumping carbon dioxide against an automated back-
pressure regulator. The sample cell in the reaction vessel was heated to the desired 
temperature and held for 1 h before recovering the solid complex by depressurisation at a rate 
of 7–8 bar min−1. The product was then homogenised in a mortar prior to further analysis. 
2.3. Analysis of the prepared binary mixtures 
2.3.1. Differential scanning calorimetry analysis (DSC) 
Thermal analysis of pure materials and the binary mixtures was carried out using a 
differential scanning calorimeter (Mettler-Toledo, LLC, UK). The equipment was 
periodically calibrated with indium. Accurately weighed samples (5 mg) were hermetically 
sealed in aluminium pans and heated at a rate of 10 °C min–1 from 50°C to 200 °C. 
2.3.2. X-ray powder diffraction analysis (XRPD) 
X-ray powder diffraction analysis of pure materials and the binary mixtures was carried out 
at room temperature using a D8 Advance X-ray Diffractometer (Bruker, Germany) in theta–
theta Bragg–Brentano geometry using reflection mode. The diffractograms were collected 
between 2–40° 2θ, with a step size of 0.006° and a counting time of 0.5 s per step using Cu 
Kα radiation. The degree of crystallinity (% Crystallinity) was determined using the 
amorphous subtraction method (Suryanarayanan, R. and Mitchell, A.G., 1985). 
2.3.3. Scanning electron microscopy analysis (SEM) 
Micrographs of pure materials and the binary systems were collected using a Hitachi SU-
8030 scanning electron microscope. The samples were securely mounted on aluminium stubs 
using double-sided adhesive tape and made electrically conductive by coating in vacuum 
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with a thin layer of chromium (~300Å) at 30 W for 30 s. The photomicrographs were 
obtained at an excitation voltage of 2.0 kV and a magnification of ×350. 
2.3.4. Solubility studies 
Saturation solubility of olanzapine was measured in triplicate by adding excess amounts of 
the drug to 10 mL of deionised water in sealed glass containers. The solutions were agitated 
for 72 hours at 37 ± 0.5 °C. The solutions were then ﬁltered (0.45 µm ﬁlter pore size) and 
assayed for drug concentration by ultra-violet spectroscopy (Cary 100 UV-vis, Agilent 
Technologies, USA) after dilution in 10 mm quartz cuvettes.  
Phase-solubility studies were carried out in triplicate as described by Higuchi and Connors 
(1965). Excess amounts of olanzapine (i.e. in amounts above its solubility limit) were added 
to 10 mL of de-ionised water (pH 7.1) containing successively increasing concentrations (0, 
5, 10, 15, 20, 25, 37.5 and 50 × 10-3 M) of Me-β-CD in sealed glass containers. The resultant 
solutions were agitated (100 rpm) at 37 ± 0.5 °C until equilibrium was attained (72 h). The 
suspensions were then ﬁltered and assayed for drug concentration as described above. The 
apparent stability constant (K1:1) for olanzapine-Me-β-CD complexes was calculated from the 
slope of the linear portion of the phase solubility diagram. 
2.3.5. Dissolution studies 
Dissolution studies of olanzapine from all binary systems and olanzapine alone were 
performed in triplicate using USP Type II paddle method (Hanson G2 Vision® Classic 6, 
Chatsworth, CA). Accurately weighed samples of drug or binary mixtures, equivalent to 10 
mg of olanzapine were dispersed into 900 mL of deionised water (pH 7.1) at 37 ± 0.5 °C and 
stirred at 50 rpm. At predetermined time points (2, 5, 10, 20, 45, and 60 min); 5 ml aliquots 
of the samples were drawn, filtered (0.45 µm ﬁlter pore size) and assayed for drug 
concentration by UV spectroscopy. The dissolution curves were characterized by the 
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percentage of drug dissolved and the dissolution efficiency at 30 minutes. Dissolution 
efficiency was evaluated according to the method reported by Khan (1975).  
2.3.6. Computational details 
Molecular docking calculations were conducted using Glide (grid-based ligand docking) 
application implemented in the Maestro 9.3 software package (Schrodinger, LLC, New York, 
2012). The Me-β-CD structure was prepared by adding hydrogens, followed by an energy 
minimisation to a convergence of RMSD 0.30Å using OPLS_2005 as force field. Olanzapine 
was energetically minimised and ionization considered at pH 7 using ionizer subprogram of 
LigPrep 2.6. The ‘Generate grid’ sub application of the Glide tool was utilised for the 
generation of grid by selecting the whole Me-β-CD structure as a receptor site to locate 
coordinates of the receptor centre. The generated grid was then utilised as a receptor for 
docking of olanzapine using the ‘standard precision’ (SP) flexible docking method, located in 
the Glide tool. Docked Me-β-CD and olanzapine complexes were visualised and molecular 
surface complex pictures were generated using Maestro. 
 
3. Results and discussions 
3.1. Differential scanning calorimetry analysis 
Fig. 1 presents the DSC thermograms of olanzapine, Me-β-CD and olanzapine-Me-β-CD 
binary systems prepared by various processing methods.  
The thermogram of olanzapine exhibited a sharp melting endotherm at ~198 °C, indicating 
the crystalline nature of the drug. DSC studies also indicated that processing the drug with 
SC-CO2 has not altered the crystallinity of the drug. Similar results were reported by 
Rudrangi et al. (2015) for indomethacin when processed with SC-CO2. Thermogram of Me-
β-CD revealed a broad endothermic peak between 60 and 120°C attributed to the release of 
water molecules as explained by Banchero et al. (2013).  
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Thermograms of the binary mixture prepared by physical mixing showed a similar diffraction 
pattern to that of the respective drug and cyclodextrin. It displayed the melting endotherm of 
olanzapine, indicating the retention of the crystalline structure of the drug and suggests the 
absence of interaction between the drug and the cyclodextrin.  
Thermograms of the binary mixtures prepared by freeze drying, co-evaporation and SC-CO2 
processing at 45 °C-100 bar, 45 °C-200 bar and 55 °C-100 bar displayed broad endothermic 
peaks of reduced intensity (as represented by arrows) compared with the melting endotherm 
of olanzapine and shifted to lower temperature. This may be ascribed to the partial inclusion 
of the drug into cyclodextrin as explained by Marques et al. (1990). On the other hand, 
thermogram of the complexes prepared by SC-CO2 processing at 55 °C-200 bar revealed a 
complete disappearance of the drug endotherm which may be ascribed to the transformation 
of drug from crystalline to an amorphous state, or the formation of inclusion complexes 
(Charoenchaitrakool et al., 2002).  
3.2. X-ray powder diffraction analysis 
Fig. 2 presents the X-ray powder diffraction patterns of pure olanzapine, Me-β-CD and 
olanzapine-Me-β-CD binary systems prepared by various processing methods.  
The diffraction pattern of olanzapine displayed sharp and intense characteristic peaks at a 
diffraction angle of 2θ equal to 8.63°, 10.36°, 12.44°, 14.64°, 17.03°, 17.81°, 18.84°, 19.85°, 
21.02°, 21.50°, 22.32°, 23.94°, 25.24°, 26.39° and 29.71° confirming the crystalline nature of 
drug. In agreement with DSC analysis, XRPD analysis also indicated that SC-CO2 process 
had not altered the crystallinity of the drug.  
The diffraction pattern of Me-β-CD showed two broad halos at 2θ equal to 11° and 18° 
confirming its amorphous nature. Diffraction pattern of the binary mixture prepared by 
physical mixing showed a similar diffraction pattern to that of the respective drug and 
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cyclodextrin. It displayed all the principal peaks of olanzapine, indicating the retention of the 
crystalline structure of drug and suggests the absence of interaction between the drug and the 
cyclodextrin.  
In agreement with the DSC results, the diffraction patterns of the complexes prepared by SC-
CO2 processing at 45 °C-200 bar and 55 °C-100 bar revealed significant diminution of the 
diffraction peaks suggesting the interactions between drug and Me-β-CD. The diffraction 
pattern of the complexes prepared by SC-CO2 processing at 55 °C-200 bar was characterised 
by the complete disappearance of the drug peaks. However, it displayed two broad features 
similar to that of the pure Me-β-CD suggesting the formation of inclusion complexes in 
which the drug was entrapped in the cavity of cyclodextrin (Charoenchaitrakool et al., 2002; 
Banchero et al,. 2013; Rudrangi et al., 2015). 
The increase in the amorphous content of the drug was observed in the following order: SC-
CO2 processing at 55 °C-200 bar (0% crystalline) > 55 °C-100 bar (4.34% crystalline) ≈  45 
°C-200 bar (6.49% crystalline) > 45 °C-100 bar (6.49% crystalline) > Co-evaporation 
(78.79% crystalline) > Freeze drying (80.17% crystalline) > Physical mixing (89.41% 
crystalline). 
3.3. Scanning electron microscopy analysis 
Morphology of olanzapine, Me-β-CD and olanzapine-Me-β-CD binary systems prepared by 
physical mixing, freeze drying, co-evaporation and SC-CO2 processing was analyzed by 
SEM and is presented in Fig. 3.  
From SEM analysis, pure olanzapine (Fig. 3a) and olanzapine processed with SC-CO2 at 55 
°C-200 bar (Fig. 3b) appeared as small to large irregularly sized and shaped crystals with a 
tendency to self-agglomerate while pure Me-β-CD (Fig. 3c) appeared as perforated hollow 
12 
 
spheres. In agreement with DSC and XRPD analyses, SEM analysis also indicated that SC-
CO2 process had not altered the crystallinity of the drug. 
The physical mixture (Fig. 3d) showed the presence of olanzapine crystals, mixed with, or 
adhered to the surface of broken hollow spheres of Me-β-CD. In agreement with the XRPD 
analysis, the complexes prepared by freeze drying (Fig. 3e) and co-evaporation (Fig. 3f) 
showed the presence of crystalline olanzapine. Co-evaporated product appeared as aggregates 
of drug particles and broken spheres. The binary mixtures prepared by SC-CO2 processing at 
55 °C-200 bar (Fig. 3g) revealed the disappearance of the original morphology of the drug 
and Me-β-CD. The product appeared as heterogeneous aggregates and it was not possible to 
differentiate between the raw materials.  
3.4. Solubility studies  
Aqueous solubility of olanzapine at 37 ± 0.5 °C was found to be 1.96 ± 0.24 µg mL-1 and 
23.49 ± 1.53 µg mL-1 at the end of 1 h and 72 h, respectively. No further improvement was 
observed in the drug solubility after 72 h. Kulkarni et al. (2010), Dixit et al. (2011) and 
Raman et al. (2013) reported a drug solubility of 13.13 ± 1.6 µg mL-1, 34.3 ± 11.1 µg mL-1 
and 43.4 ± 1.74 µg mL-1 in distilled water at 37 °C, respectively.  
Fig. 4 presents the phase solubility diagram for the complex formation between olanzapine 
and Me-β-CD in deionized water at 37 ± 0.5 °C. The studies revealed that the apparent 
solubility of olanzapine increased linearly as a function of Me-β-CD concentration over the 
entire concentration range studied. Linearity is a characteristic of AL-subtype system, 
suggesting the formation of water soluble complexes in solution as explained by Higuchi and 
Connors (1965). Moreover, the linear (olanzapine and Me-β-CD) correlation with slope of 
less than 1 (0.0223) suggested the formation of 1:1 complexes over the concentration range 
(0–50 mM) investigated. The apparent stability constant (K1:1), obtained from the slope of the 
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linear phase solubility diagram was 304 M-1.Similar phase solubility profile was reported for 
olanzapine-Me-β-CD complexes in distilled water by de Freitas et al. (2012).  
Phase solubility studies of olanzapine-hydroxypropyl-β-cyclodextrin complexes were carried 
out by Kulkarni et al. (2010) in distilled water and the authors reported a stability constant of 
K1:1 = 242 M-1. Phase solubility studies of indomethacin-Me-β-CD complexes were carried 
out by Rudrangi et al. (2015) in phosphate buffer medium (pH 7.4) and the authors reported 
an AN-subtype phase solubility diagram with a stability constant of K1:1 = 167 M-1. 
3.5. Dissolution studies  
Fig. 5 presents the dissolution profiles of olanzapine from drug alone and from drug-Me-β-
CD binary systems in deionised water at 37 ± 0.5 °C. All binary systems other than the 
physical mixture exhibited better dissolution profiles than the drug alone. The results in terms 
of percent of olanzapine dissolved at 30 min and the dissolution efficiency at 30 min are 
presented in Table 2. 
The increase in the dissolution properties of olanzapine was observed in the following order: 
SC-CO2 processing at 55 °C-200 bar > 55 °C-100 bar ≈  45 °C-200 bar > 45 °C-100 bar > co-
evaporation > freeze drying > physical mixing. 
The amount of olanzapine dissolved from unprocessed drug alone and drug processed with 
SC-CO2 at 55 °C-200 bar was very low with 17.62 ± 1.59% and 18.84 ± 1.44% dissolving at 
the end of 60 min, respectively. The dissolution studies confirmed that SC-CO2 processing 
alone had not affected the dissolution of the drug.  
The binary mixture obtained by physical mixing exhibited no increase in the drug dissolution 
with 16.75 ± 1.72% of olanzapine dissolving at the end of 60 min. Similar dissolution profile 




Improvement in the drug dissolution was found to be dependent both on the processing 
method and the processing conditions used for the preparation of complexes. The binary 
mixtures prepared by freeze drying and co-evaporation exhibited an increased drug release 
with 34.44 ± 2.61% and 68.67 ± 3.11% of olanzapine dissolved after 60 min, respectively. 
On the other hand, binary mixtures prepared by SC-CO2 processing resulted in more than 
80% of drug dissolution within the first 30 min irrespective of the temperature and pressure 
employed. However, the binary mixtures prepared by SC-CO2 processing at 55 °C and 200 
bar showed highest drug dissolution with more than 90% of the drug dissolved within the 
first 10 min. These results suggested that both the temperature and pressure have influence on 
the formation of the inclusion complexes in SC-CO2 at studied parameters. 
The improved dissolution characteristics of the binary mixtures can be attributed to the 
improved drug wettability, high aqueous solubility (greater than 2000 mg mL-1) and 
surfactant-like properties of Me-β-CD as suggested by Banchero et al. (2013), Cirri et al. 
(2005) and Guyot et al. (1995). Moreover, the greater improvement obtained with all the SC-
CO2 processed systems could also be a result of reduced crystallinity of the binary mixtures 
(El-Badry, M. et al., 2009) and the formation of inclusion complexes between olanzapine and 
Me-β-CD in the solid state (Rudrangi et al., 2015). 
3.6. Docking studies  
Computational molecular docking studies were conducted to study the possibility of 
molecular arrangement of inclusion complexes between olanzapine and Me-β-CD. Fig. 6 
presents the best pose of olanzapine docked in the cavity of Me-β-CD.  
The three-dimensional structure of olanzapine is depicted in stick form with a mesh 
representing the molecular surface (grey with reddish tint in the cavity); the hydrophilic area 
(cyan mesh) and the hydrophobic area (orange mesh at the mid cavity depth of Me-β-CD). 
The figure shows the binding of olanzapine in the cavity of Me-β-CD through anchorage by 
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the methyl group of the piperazine due to its hydrophobicity. The interactions responsible for 
the inclusion seem to be purely hydrophobic in nature, as no indications of hydrogen bonding 
can be found in the optimal complex geometries. The binding affinity (GLIDE energy), van 
der Waals energy and docking score for inclusion of olanzapine in Me-β-CD are -24.13 kcal 
mol-1, -21.57 kcal mol-1 and -3.09 kcal mol-1, respectively.  
Computational molecular docking studies of indomethacin with Me-β-CD were carried out 
by Rudrangi et al. (2015) using the Glide application and the authors reported the binding 
affinity, van der Waals energy and docking score of 27.880 kcal mol-1, -28.941 kcal mol-1 and 
-4.882 kcal mol-1 respectively.  
 
4. Conclusions 
Complexation of olanzapine with Me-β-CD was accomplished successfully using a single-
step, organic solvent-free supercritical fluid process. The phase solubility diagram with Me-
β-CD in de-ionised water was classiﬁed as AL–subtype, indicating the formation of 1:1 
stoichiometric inclusion complexes. All the binary mixtures with Me-β-CD, except physical 
mixture, exhibited a faster and greater extent of drug dissolution than the drug alone. 
Information obtained from the differential scanning calorimetry, X-ray powder diffraction, 
scanning electron microscopy and dissolution studies suggest complete complexation or 
amorphisation of olanzapine and Me-β-CD prepared by SC-CO2 processing method. 
Different degrees of crystallinity and dissolution rate were observed in the products 
processed by SC-CO2 at various processing conditions, suggesting the possibility of 
olanzapine-Me-β-CD interactions of different efficiencies in the solid state. Products obtained 
by the SC-CO2 processing method exhibited the highest apparent drug dissolution followed 
by co-evaporation, freeze drying and physical mixing. Therefore, a solid inclusion method 
using SC-CO2 proved to be a novel and efficient complexation method for olanzapine into 
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Me-β-CD. Furthermore, since this method has no toxic solvent residue, products obtained by 
this method should provide minimal side effects in humans, compared to those obtained by 
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Fig. 1. DSC thermograms of olanzapine, Me-β-CD and olanzapine-Me-β-CD binary systems 
prepared by various processing methods  
Fig. 2. X-ray powder diffractograms of olanzapine, Me-β-CD and olanzapine-Me-β-CD 
binary systems prepared by various processing methods 
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Fig. 3. SEM photomicrographs of olanzapine-unprocessed (a), olanzapine processed with 
SC-CO2 at 55 °C-200 bar (b), Me-β-CD (c) and olanzapine-Me-β-CD binary systems 
prepared by physical mixing (d), freeze drying (e), co-evaporation (f) and SC-CO2 processing 
at 55 °C-200 bar (g).  
Fig. 4. Phase solubility studies of olanzapine with increasing concentrations of Me-β-CD at 
37 ± 0.5 °C and in deionized water-pH 7.1. 
Fig. 5. Dissolution proﬁles of olanzapine and olanzapine-Me-β-CD binary systems prepared 
by various processing methods at 37 ± 0.5 °C and in deionised water (n=3). 
Fig. 6. Representation of the complex between Me-β-CD (orange) and olanzapine (stick 





Table 1. Drug-cyclodextrin complexes prepared by SC-CO2 processing in static or dynamic 
modes.  
 
Drug Cyclodextrin Mode Reference 
Acetaminophen  β-CD Not reported Giordano et al., 1996. 




Al-Marzouqi et al., 2007a  
Al-Marzouqi et al., 2007b 




Bandi et al., 2004   
Toropainen et al., 2006 
Bupivacaine β-CD Static Al-Marzouqi et al., 2007b 
Econazole β-CD Static Al-Marzouqi et al., 2007c 
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Papet et al., 2003 
Rodier et al., 2005 
Fluconazole β-CD Static Al-Marzouqi et al., 2009 







Charoenchaitrakool et al., 2002 
Türk et al., 2007 
Hussein et al., 2007 





Bandi et al., 2004   
Rudrangi et al., 2015 






Al-Marzouqi et al., 2006 
Al-Marzouqi et al., 2009 
Hassan et al., 2007 
Ketoprofen  Me-β-CD Static Banchero et al., 2013 





Van Hees et al., 2002 





Moribe et al., 2007 
Junco et al., 2002  





Van Hees et al., 1999 
Van Hees et al., 2002 
Grandelli et al., 2012 
Simvastatin HP-β-CD Dynamic Jun et al., 2007 
 
*In static mode, the contents of the cell are exposed to carbon dioxide, pressurized and allowed to equilibrate; 
while carbon dioxide is circulated continuously through the cell in the dynamic mode. 




























Table 2: Percent olanzapine dissolved (DP) at 30 min and dissolution efﬁciency (DE)* at 30 
min from olanzapine and olanzapine-Me-β-CD binary systems prepared by various 
processing methods (USP Apparatus II; deionised water-pH 7.1; 37 ± 0.5 °C; 100 rpm; n=3). 
 
Sample (Method) DP 30  DE30  
Olanzapine 11.31 ± 1.52   5.7  
Physical mixing 11.51 ± 1.57   7.6  
Freeze drying 21.75 ± 2.42 17.3  
Co-evaporation  65.42 ± 3.04 62.1  
Supercritical carbon dioxide processing   
     45 °C-100 bar 80.15 ± 3.06 71.1  
     45 °C-200 bar 86.23 ± 3.42 80.8  
     55 °C-100 bar 85.47 ± 3.18 79.6  
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     55 °C-200 bar 93.28 ± 2.79 88.8  
 
 
*DE30 was calculated from the area under the dissolution curve at 30 min and expressed as a percentage of the 
area of the rectangle described by 100% dissolution in the same time of the total amount added.  
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